Diversity of Investigative Site Staff Highly Associated with the Diversity of Patients Enrolled in Clinical Trials, According to Tufts Center for the Study of Drug Development
November 02, 2021 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- A new study just released by the Tufts Center for the Study of Drug Development (CSDD) shows that the proportion of a given race or ethnicity among...
Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Clinical Trials, According to Tufts Center for the Study of Drug Development
May 04, 2021 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Increasing complexity of clinical trials targeting cancer—including use of more sophisticated scientific designs, larger global scope, and greater focus on...
Planned and Unplanned Mid-Study Updates Pose Major Challenge to Clinical Trial Timelines, According to Tufts Center for the Study of Drug Development
March 02, 2021 09:00 ET
|
Tufts Center for the Study of Drug Development
Tufts Center for the Study of Drug Development Analysis Finds Larger Pharmaceutical Companies Experience Longer Delays due to Mid-Study Updates BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Planned...
Rising Protocol Design Complexity Is Driving Rapid Growth in Clinical Trial Data Volume, According to Tufts Center for the Study of Drug Development
January 12, 2021 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Ever more complex clinical trial designs are collecting much higher volumes of data from a variety of sources, intensifying pressure on drug sponsors to...
Kenneth I Kaitin to Retire from the Tufts Center for the Study of Drug Development after Leading the Organization for 23 Years
December 08, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Tufts Center for the Study of Drug Development (CSDD), the leading independent source of authoritative analyses on the nature and pace of pharmaceutical...
Transition to Decentralized Clinical Trials during the Coronavirus Pandemic Is far More Nuanced than Expected, According to Tufts Center for the Study of Drug Development
November 12, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- The coronavirus pandemic has facilitated rapid adoption of decentralized clinical trial execution, with more than half of all global clinical trials now...
New Anti-infective Drugs Had a 14% Speed Advantage vs. Other Drugs During 2000-19, According to Tufts Center for the Study of Drug Development
September 15, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- New anti-infective drugs that won marketing approval in the United States during the last two decades took 14% less time to undergo clinical trials and...
MEDIA ADVISORY: Expert Commentary and Insight Available on COVID-19 Drug Development
August 06, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
Perspectives on COVID-19 Vaccine and Therapeutic Development from Tufts Center for the Study of Drug Development BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Experts from the Tufts Center for the...
Faster New Drug Approval Times Are More Than Offset by Longer Clinical Times in U.S., According to Tufts Center for the Study of Drug Development
July 16, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Although regulatory approval time for new drugs in the United States is shortening, the time needed, on average, to complete clinical development of those...
Tufts Center for the Study of Drug Development Establishes Demographic Benchmarks for Pivotal Clinical Trials, Showing Areas of Under-Representation
May 12, 2020 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Although up to 90% of pivotal clinical trials for drugs approved for sale in the United States provide data on study participants by sex, race, and age, less...